Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01WUA
|
|||
| Former ID |
DAP001214
|
|||
| Drug Name |
Treprostinil
|
|||
| Synonyms |
Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H34O5
|
|||
| Canonical SMILES |
CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
|
|||
| InChI |
1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
|
|||
| InChIKey |
PAJMKGZZBBTTOY-ZFORQUDYSA-N
|
|||
| CAS Number |
CAS 81846-19-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14854155, 14878554, 23950807, 43529534, 46504572, 47207871, 50304326, 56394875, 57371812, 114787499, 128887520, 134224636, 135014308, 136933659, 137249659, 143205120, 162205084, 163138465, 164234753, 170467450, 174548947, 175265596, 178102445, 179117156, 223938513, 230287018, 250136886, 252356445, 252457273, 252469194
|
|||
| ChEBI ID |
CHEBI:50861
|
|||
| ADReCS Drug ID | BADD_D02268 ; BADD_D02269 | |||
| SuperDrug ATC ID |
B01AC21
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostacyclin receptor (PTGIR) | Target Info | Agonist | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Vascular smooth muscle contraction | ||||
| Platelet activation | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin | |||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | |||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Small Ligand GPCRs | ||||
| Endothelin Pathways | ||||
| Platelet homeostasis | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5820). | |||
| REF 2 | Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. | |||
| REF 3 | Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.